Title:
ENGINEERED IMMUNE CELL AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/083003
Kind Code:
A1
Abstract:
Provided is an engineered immune cell comprising exogenous IL9 or a modified promoter operably linked to endogenous IL9 to enhance expression of IL9, and optionally a chemokine and/or a cell surface molecule that specifically recognizes an antigen. Further provided is a use of the engineered immune cell in the treatment of cancer, infections or autoimmune diseases. Compared with traditional engineered immune cells, the engineered immune cell of the present invention has significantly improved tumor-killing activity.
Inventors:
XING YUN (CN)
REN JIANGTAO (CN)
REN JIANGTAO (CN)
Application Number:
PCT/CN2022/127718
Publication Date:
May 19, 2023
Filing Date:
October 26, 2022
Export Citation:
Assignee:
BIOHENG THERAPEUTICS LTD (GB)
International Classes:
C12N5/074; A61K35/17; A61K35/545; A61K39/395; A61P35/00; C12N5/0783; C12N5/0789
Domestic Patent References:
| WO2021040736A1 | 2021-03-04 | |||
| WO2021077117A1 | 2021-04-22 |
Foreign References:
| CN111556892A | 2020-08-18 | |||
| CN106117341A | 2016-11-16 | |||
| CN111542594A | 2020-08-14 | |||
| CN111954715A | 2020-11-17 | |||
| CN113574168A | 2021-10-29 |
Other References:
DATABASE Protein NCBI; 26 October 2021 (2021-10-26), ANONYMOUS : "interleukin-9 precursor [Mus musculus] ", XP093066149, Database accession no. NP_032339.1
Attorney, Agent or Firm:
FOUNDIN INTELLECTUAL PROPERTY (CN)
Download PDF: